PPT Slide
ETC-216: AIM (ApoA-I Milano)
- Carriers are protected against vascular disease
- AIM enhances the RLT pathway
- HDL transports excess cholesterol from arteries
to the liver for removal
- Anti-atherosclerotic effects in preclinical models
including rapid plaque stablization
- Phase I SDT complete, Phase II ongoing
Variant of ApoA-I, the Major HDL Protein